An acute awareness of the profound social and medical costs associated with heroin and opiate addiction in New Mexico has led a group of advocates from public health, state and local governments, corrections, academia, and community activists to collaborate for the purpose of increasing access to medication-assisted therapy (MAT) with buprenorphine and methadone in New Mexico. This paper describes these collaborations, with a focus on the evolution of harm reduction approaches to substance abuse disorders and successful efforts to make MAT available to incarcerated persons.
ShahN. “New Mexico Epidemiology Report, November 20, 2009, Volume 2009, Number 9”. In Unintentional Illicit and Prescription Drug Overdose Death Trends, 2008, Santa Fe, NM: New Mexico Department of Health.
2.
JosephH, StancliffS and LangrodL. 2000. Methadone maintenance treatment (MMT): a review of historical clinical issues. Mt. Sinai J Med., 67: 347–364.
KinlockT W, GordonM S, SchwartzR P, FitzgeraldT T and O'GradyK E. 2009. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat, 37: 277–285.
5.
American Public Health Association (APHA). 2003. Standards for Health Services in Correctional Institutions. Developed by APHA Task Force on Correctional Health Care Standards, 3rd Edition Task Force, Washington, DC: American Public Health Association.
6.
LiptonD S. 1992. “Correctional drug abuse treatment in the United States: an overview”. In Drug Abuse Treatment in Prisons and Jails, Edited by: LeukefeldC G and TimsF M. 192–210. Washington, DC: National Institute on Drug Abuse Research Monograph Series.
7.
National Institutue of Drug Abuse (NIDA). Principles of Drug Abuse Treatment for Criminal Justice Populations: A Research-Based Guide, Washington, DC: National Institute of Drug Abuse. NIH Document No. 06-5316, Revised 2007. Available at: http://www.nida.nih.gov/PDF/PODAT_CJ/PODAT_CJ.pdf. Accessed December 6, 2011
8.
National Commission on Correctional Health Care (NCCHC). 2008. Managing Addicts Inmates: Medication Assisted Therapy in Corrections, Chicago, IL: NCCHC. CD-ROM Self-Study Program
9.
MøllerL, StöverH, JürgensR, GathererA and NikogosianH. 2007. Health in Prisons: A WHO Guide to the Essentials in Prison Health, Geneva: World Health Organization.
10.
NunnA, ZallerN, DickmanS, TrimburC, NijhawanA and RichJ D. 2009. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend, 105: 83–88.
11.
RichJ D, BoutwellA EShieldD C. 2005. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health, 82: 411–419.
12.
McClemoreM. 2009. Barred From Treatment: Punishment of Drug Users in New York State Prisons, New York: Human Rights Watch.
13.
ChandlerR K, FletcherB W and VolkowN D. 2009. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA, 301: 183–190.
14.
KangS Y, DerenS, AndiaJ, ColonH M, RoblesR and Oliver-VelezD. 2005. HIV transmission behaviors in jail/prison among Puerto Rican drug injectors in New York and Puerto Rico. AIDS Behav., 9: 377–386.
15.
Centers for Disease Control and Prevention (CDC). 2003. Wound Botulism Among Black Tar Heroin Users, Washington, DC: Centers for Disease Control and Prevention.
16.
KrinskyC S, LathropS L, BrownP and NolteK B. 2009. Drugs, detention, and death: a study of the mortality of recently released prisoners. Am J Forensic Med Pathol, 30: 6–9.
17.
BinswangerI A, SternM FDeyoR A. 2007. Release from prison—a high risk of death for former inmates. N Engl J Med, 356: 157–165.
18.
BirdS M and HutchinsonS J. 2003. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996–99. Addiction, 98: 185–190.
19.
Albizu-GarciaC, Caraballo CorreaGHernandez ViverA D. 2007. Buprenorphine-naloxone treatment for pre-release opioid dependent inmates in Puerto Rico. J Addict Med, 1: 126–132.
20.
GordonM S, KinlockT W, SchwartzR P and O'GradyK E. 2008. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction, 103: 1333–1342.
21.
KinlockT, GordonM, FitzgeraldT and SchwartzR. 2010. Developing and implementing a new prison-based buprenorphine treatment program. J Offender Rehab., 49: 91–109.
22.
KinlockT W, BattjesR J and SchwartzR P. 2002. A novel opioid maintenance program for prisoners: preliminary findings. J Subst Abuse Treat, 22: 141–147.
23.
KinlockT W, BattjesR J and SchwartzR P. 2005. A novel opioid maintenance program for prisoners: report of post-release outcomes. Am J Drug Alcohol Abuse, 31: 433–454.
24.
KinlockT W, GordonM S, SchwartzR P and O'GradyK E. 2008. A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav, 35: 34–47.
25.
KinlockT W, GordonM S, SchwartzR P, O'GradyK, FitzgeraldT T and WilsonM. 2007. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend, 91: 220–227.
26.
McKenzieM, MacalinoG, McClungC, ShieldD C and RichJ D. 2005. Opiate replacement therapy at time of release from incarceration: project MOD, a pilot program. J Opioid Manag, 1: 147–151.
27.
SamuelM, DohertyP, BulterysM and JenisonS. 2001. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect, 127: 475–484.
28.
McMillanG P and LaphamS C. 2005. Staff perspectives on methadone maintenance therapy (MMT) in a large southwestern jail. Addict Res Theory, 13: 53–63.
29.
McMillanG P, LaphamS and LackeyM. 2008. The effect of a jail methadone maintenance therapy (MMT) program on inmate recidivism. Addiction, 103: 2017–2023.
30.
HildebranG. 2009. “Release, relapse, and treatment”. Available online at ECHO Web site: http://echo.unm.edu/Videos.shtml. Accessed October 6, 2010
